Inovio Pharmaceuticals (INO) Receivables (2010 - 2026)

Inovio Pharmaceuticals has disclosed Receivables across 17 years of filings, most recently posting $41000.0 for Q2 2026.

• In Q2 2026, Receivables fell 95.12% year-over-year to $41000.0; the TTM figure through Jun 2026 stood at $41000.0 (down 95.12% YoY), while the FY2025 annual figure was $450.0, down 99.96% from the prior year.
• Receivables came in at $41000.0 for Q2 2026 at Inovio Pharmaceuticals, up from $34000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $19.9 million in Q4 2022 to a low of $450.0 in Q4 2025.
• Average Receivables over 5 years is $4.1 million, with a median of $2.0 million recorded in 2023.
• Year-over-year, Receivables soared 221.56% in 2022 and slumped 99.96% in 2025.
• Over 5 years, Receivables stood at $19.9 million in 2022, then plunged by 87.94% to $2.4 million in 2023, then sank by 50.15% to $1.2 million in 2024, then tumbled by 99.96% to $450.0 in 2025, then surged by 9011.11% to $41000.0 in 2026.
• Per Business Quant data, the three most recent Receivables figures were $41000.0 in Q2 2026, $34000.0 in Q1 2026, and $450.0 in Q4 2025.